Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma

This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at guidance.nice.org.uk/ta178

Important information about this guidance

This guidance was developed using the NICE multiple technology appraisals process: www.nice.org.uk/aboutnice/howwework/devnicetech